Op-Ed: Terry Wilcox: Why Most Favored Nation pricing risks putting America last

Washington Reporter

America's patients deserve the world's best healthcare — innovative treatments that save lives, delivered at prices that don't bankrupt families. For too long, we've subsidized global drug innovation while bearing the brunt of the costs, with Americans paying three times more for brand-name drugs than in other OECD countries, even after discounts.

President Donald J. Trump's aggressive actions to end this injustice — demanding that pharmaceutical companies provide the best prices to Americans — marks a pivotal moment in putting our nation first.

In July, the White House outlined a clear directive to manufacturers: implement most-favored-nation (MFN) pricing for Medicaid patients, ensure no sweeter deals abroad for new drugs, enable direct-to-patient sales at those rates, and leverage trade policies to hike international prices while redirecting savings to U.S. consumers. This was amplified in early August with pointed warnings, including potential tariffs of up to 250 percent on imported drugs if compliance isn't met by September 29.

Read more here.